Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910073/S193

ENDOTAK LEAD SYSTEM

Boston Scientific · Decision date Sep 17, 2026

FDA DECISIONP910073/S193

What did the FDA approve?

FDA records P910073/S193 as a supplement to PMA P910073, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 17, 2026.

FDA approval order statement

approval for supplemental labeling for the ENDOTAK RELIANCE ePTFE family of defibrillator leads to align with a July 2025 Product Advisory.
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Sep 17, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P910073/S193
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Sep 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P910073. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P910073 · Original PMA

    ENDOTAK LEAD SYSTEM

  2. P910073/S193 received

    Application receipt date recorded by FDA.

  3. P910073/S193 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P910073. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910073

Product / regulatory recordCompanyPathwayDecision dateSource
Boston ScientificPMA approvalAug 26, 1993FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records